BRAF and intestinal neoplasm: Third, murine and human intestinal tumors with KRAS mutations are mostly MSI-stable or MSI-low (Noffsinger, 2009; Bennecke et al., 2010), whereas BRAF mutant human tumors are frequently MSI-high (Rajagopalan et al., 2002).